Invitation Letter

2025/05/09

Beilu pharma is delighted to to extend a warm invitation to you to make an appointment in CPHI China June 24-26 at Shanghai.

Our Booth Number is E3A49.

References

Related News

[New Product] Beilu Pharmaceutical's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Approved
December 15, 2025Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for Pioglitazone Hydrochloride and Metformin H...view
Beijing Beilu Pharmaceutical's subsidiary, Hichi Pharmaceutical, has obtained GMP certification from the Brazilian National Health Surveillance Agency (ANVISA)
September 2, 2025Recently, the company's holding subsidiary, Hichi Pharmaceutical, passed the official on-site GMP (Good Manufacturing Practice) certification of the Brazilian National Health Surveillance Agency (...view
Good News: Beilu Pharmaceutical won the 2020 National Adverse Drug Reactions Monitoring and Evaluation Excellent Unit
April 12, 2021On March 11th, the National Medical Products Administration (NMPA) issued the “Notice Recognizing Excellent Units in the National Adverse Drug Reactions Monitoring and Evaluation 2020”.view
Beilu Pharmaceutical Plans to Acquire Tianyuan Pharmaceutical, Actively Building "Second Growth Curve"
March 1, 2024Recently, Beilu Pharmaceutical announced that it plans to use its own funds to acquire 80% of the equity of Chengde Tianyuan Pharmaceutical Co., Ltd. After the completion of this acquisition, Tianyuan...view
[New Product] Beilu Pharma Secures Approval for Iomeprol Injection
August 27, 2024Recently, Beijing BeiLu Pharmaceutical Co., Ltd. (BeiLu Pharma) obtained the Drug Registration Certificate for Iomeprol Injection, officially approved and issued by the National Medical Products Admin...view
To Understand the Development of Iodinated Contrast Agents
May 13, 2021For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of the body's local tissues.view

Invitation Letter

[New Product] Beilu Pharmaceutical's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Approved

Beijing Beilu Pharmaceutical's subsidiary, Hichi Pharmaceutical, has obtained GMP certification from the Brazilian National Health Surveillance Agency (ANVISA)

Good News: Beilu Pharmaceutical won the 2020 National Adverse Drug Reactions Monitoring and Evaluation Excellent Unit

Beilu Pharmaceutical Plans to Acquire Tianyuan Pharmaceutical, Actively Building "Second Growth Curve"

[New Product] Beilu Pharma Secures Approval for Iomeprol Injection

To Understand the Development of Iodinated Contrast Agents